BridgeMD
Impact of beta blocker administration on aortic valve replacement
EU CTIS ID: 2024-518731-11-00
What this study is testing
The aim of the study is to investigate the impact of beta blocker administration among subjects undergoing transcatheter aortic valve replacement (TAVR).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Informed Consent must be signed by the subject prior to any study intervention.
- Adult patients (› 18 years) with severe symptomatic aortic stenosis eligible and scheduled for elective TAVR and are able to give consent.
- Indication for B-blocker therapy with a prior treatment duration of at least 1 month before inclusion.
You likely can't join if
- Emergency or urgent indication for TAVR.
- Being in a dependent relationship with the trial site.
- Participation in another study with investigational drug within the 30 days preceding and during the present study.
- Previous enrolment into the current study.
- Pregnancy or breast feeding women.
- Hemodynamically unstable patients receiving inotropic medication.
See the full eligibility criteria
- Informed Consent must be signed by the subject prior to any study intervention.
- Adult patients (› 18 years) with severe symptomatic aortic stenosis eligible and scheduled for elective TAVR and are able to give consent.
- Indication for B-blocker therapy with a prior treatment duration of at least 1 month before inclusion.
- Emergency or urgent indication for TAVR.
- Being in a dependent relationship with the trial site.
- Participation in another study with investigational drug within the 30 days preceding and during the present study.
- Previous enrolment into the current study.
- Pregnancy or breast feeding women.
- Hemodynamically unstable patients receiving inotropic medication.
- Prior permanent pacemaker implantation.
- Existing indication for pacemaker implantation.
- Hemodynamic relevant left ventricular outflow tract obstruction.
- Prior intolerance of B-blocker medication.
- Life expectancy ‹ 1 year.
- Known or suspected non-compliance, drug, or alcohol abuse.
- Inability to give consent, or follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.
The study team makes the final eligibility decision.
Where it's taking place
- Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.